Rossmore Private Capital lowered its position in shares of Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 56.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,322 shares of the company’s stock after selling 18,817 shares during the period. Rossmore Private Capital’s […]
Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) was the target of a large increase in short interest during the month of June. As of June 30th, there was short interest totalling 2,830,000 shares, an increase of 6.4% from the June 15th total of 2,660,000 shares. Approximately 6.2% of the shares of the company are short […]
NEW HAVEN, Conn., June 15, 2023 Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Timothy Shannon,. | June 15, 2023
05.06.2023 - NEW HAVEN, Conn., June 05, 2023 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two .
Finepoint Capital LP raised its stake in shares of Arvinas, Inc. (NASDAQ:ARVN – Get Rating) by 7.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 429,600 shares of the company’s stock after buying an additional 30,600 shares during the quarter. Arvinas comprises […]